Program
Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103
Its studies are led by ABL Bio.
Furthest: phase 2, since Aug 8, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ABL Bio | 22 open or running | phase 2since Aug 8, 2025 | Nov 2, 2023 | Dec 2, 2027phase 2 · NCT07158918 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT06126666 · 96 planned · South Korea
- Aug 8, 2025Phase 2 study in Solid TumorsNCT07158918 · 65 planned · United States, Australia, South Korea
Ahead
- Dec 2, 2027Primary completion: phase 2 study in Solid TumorsNCT07158918
TargetBeta
“A T-cell engaging (TCE) bispecific antibody against both the tumor-associated antigen (TAA) B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07158918Solid Tumors · United States, Australia, South Korea | 2 | Recruiting | Dec 2, 2027 | 65 |
| NCT06126666Advanced Solid Tumor · South Korea | 1 | Recruiting | Dec 30, 2025 | 96 |
How it is read
Names in the registry
- “ABL103”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.